HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers
The company’s groundbreaking drug encapsulated immunoliposomes may represent a significant improvement over existing antibody drug…